T
Triagenics
Innovative one-minute procedure preventing wisdom teeth formation with minimal invasiveness and high efficacy
About Triagenics
Triagenics operates in the dental healthcare market, specializing in a revolutionary procedure designed to prevent the formation of wisdom teeth. The company's core product is the TBA (Tooth Bud Ablation) one-minute procedure, which gently warms the center of developing wisdom tooth buds to block their formation. This minimally invasive procedure is designed for safety, efficacy, and simplicity, making it easier than a standard one-surface filling. Triagenics primarily serves dental professionals and clinics looking for advanced solutions to manage wisdom teeth in patients. The business model revolves around providing this specialized service, generating revenue through the sale and licensing of their proprietary TBA technology to dental practices. The market for this innovation includes dental care providers globally who seek to reduce the complications and costs associated with traditional wisdom tooth extraction.
Source: Dealroom company dataAt a glance
- Founded
- 2016
- Headquarters
- Redmond, United States
- Sector
- Health Tech & Medtech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
StartEngine- AVAsclepius Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Triagenics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Triagenics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.